{"_id": "64ff8e278ed67004cfc73a87", "nctID": "NCT02862275", "booleanRepresentation": "{\n    \"$and\":[\n        {\n            \"$and\": [\n                {\"$or\": [\n                    {\"histologically confirmed malignancy\"},\n                    {\"pathologically confirmed malignancy\"}\n                ]},\n                {\"$or\": [\n                    {\"metastatic malignancy\"},\n                    {\"unresectable malignancy\"}\n                ]},\n                {\"$not\": {\"$or\": [\n                    {\"standard of care therapy exists\"},\n                    {\"standard of care therapy is effective\"}\n                ]}}\n            ]\n        },\n        {\n            \"$and\": [\n                {\"ACT infusion prior to study enrollment\"},\n                {\"$or\": [\n                    {\"ACT with tumor infiltrating lymphocytes (TIL)\"},\n                    {\"human leukocyte antigen (HLA)-class I T cell receptor (TCR)-engineered lymphocytes\"},\n                    {\"HLA-class II TCR-engineered lymphocytes\"},\n                    {\"chimeric antigen receptor (CAR)-engineered T cells\"}\n                ]}\n            ]\n        },\n        {\n            \"$and\": [\n                {\"prior ACT therapy completed\"},\n                {\"$or\": [\n                    {\"radiographic progression of disease\"},\n                    {\"active disease observed on biopsy\"},\n                    {\"$and\": [\n                        {\"pre-treatment biopsy demonstrating viable tumor cells\"},\n                        {\"clinical progression of disease\"}\n                    ]}\n                ]}\n            ]\n        },\n        {\n            \"$and\": [\n                {\"solid tumor patients have measurable disease\"},\n                {\"$or\": [\n                   "}